Dr. Kris Ann Schultz, MD
Claim this profileChildren's Hospital's and Clinics of Minnesota
Studies Osteosarcoma
Studies Ewing Sarcoma
3 reported clinical trials
9 drugs studied
Area of expertise
1Osteosarcoma
EWSR1-FLI1 translocation positive
EWS rearrangement positive
2Ewing Sarcoma
EWSR1-FLI1 translocation positive
EWS rearrangement positive
Affiliated Hospitals
Clinical Trials Kris Ann Schultz, MD is currently running
Onivyde + Talazoparib/Temozolomide
for Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm. In Arm A, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair, the cancer cells may die. In Arm B, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and temozolomide. Both of these medications work by damaging the DNA of the cancer call which may cause the tumor(s) to die. Once the highest doses are reached in Arm A and Arm B, then "expansion Arms" will open. An expansion arm treats more children and AYAs with recurrent or refractory solid tumors at the highest doses achieved in the phase I study. The goal of the expansion arms is to see if the tumors go away in children and AYAs with recurrent or refractory solid tumors. There will be 3 "expansion Arms". In Arm A1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and talazoparib. In Arm A2, children and AYAs with recurrent or refractory solid tumors, whose tumors have a problem with repairing DNA (identified by their doctor), will receive Onivyde and talazoparib. In Arm B1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and temozolomide. Once the highest doses of medications used in Arm A and Arm B are determined, then a phase II study will open for children or young adults with Ewing sarcoma that has recurred or is refractory following treatment received after the initial diagnosis. The trial will test the same 2 combinations of therapy in Arm A and Arm B. In the phase II, a participant with Ewing sarcoma will be randomly assigned to receive the treatment given on either Arm A or Arm B.
Recruiting1 award Phase 1 & 214 criteria
Liquid Biopsy
for Bone Cancer
This trial is testing a blood test that looks for small pieces of tumor DNA in patients with Ewing sarcoma or osteosarcoma. The goal is to see if this test can help predict if the cancer will return after treatment. A group of patients will participate to help researchers understand how useful this test can be.
Recruiting1 award N/A15 criteria
More about Kris Ann Schultz, MD
Clinical Trial Related15 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Kris Ann Schultz, MD has experience with
- Ifosfamide
- Cyclophosphamide
- Doxorubicin
- Vincristine
- Dactinomycin
- Temozolomide
Breakdown of trials Kris Ann Schultz, MD has run
Peripheral Neuroepithelioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kris Ann Schultz, MD specialize in?
Kris Ann Schultz, MD focuses on Osteosarcoma and Ewing Sarcoma. In particular, much of their work with Osteosarcoma has involved EWSR1-FLI1 translocation positive patients, or patients who are EWS rearrangement positive.
Is Kris Ann Schultz, MD currently recruiting for clinical trials?
Yes, Kris Ann Schultz, MD is currently recruiting for 2 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Kris Ann Schultz, MD has studied deeply?
Yes, Kris Ann Schultz, MD has studied treatments such as Ifosfamide, Cyclophosphamide, Doxorubicin.
What is the best way to schedule an appointment with Kris Ann Schultz, MD?
Apply for one of the trials that Kris Ann Schultz, MD is conducting.
What is the office address of Kris Ann Schultz, MD?
The office of Kris Ann Schultz, MD is located at: Children's Hospital's and Clinics of Minnesota, Minneapolis, Minnesota 55404 United States. This is the address for their practice at the Children's Hospital's and Clinics of Minnesota.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.